2026 Q2 Portfolio Activity
In 2026 Q2, Artal Group S.A. maintained a portfolio of 2 distinct positions. They heavily accumulated shares in Lexicon Pharmaceuticals Inc, increasing the position by 13.2%. The fund also reduced its exposure to Cava Group Inc by 31.6%.
Position History
hover any row below to update
Loading…
Total Positions
2
Quarter
2026 Q2
Top Holding
CAVA (54.9%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-2 of 2
Artal Group S.A. Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CAVA
Cava Group Inc
|
Consumer Cyclical | 54.85% | 76.11% |
#1
Prev: #1
|
6.0 |
—
|
-3,000,000 | -31.6% |
P
S
|
6,507,990 | $510,747,055 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
LXRX
Lexicon Pharmac...
|
Healthcare | 45.15% | 23.89% |
#2
Prev: #2
|
7.5 |
—
|
20,421,735 | 13.2% |
P
S
|
175,156,062 | $420,374,549 | 2015 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 |
Showing 1-2 of 2 holdings